Switzerland SMI Concentration Rises as Novartis Falls

The market’s reaction shows why that distinction matters. Novartis sold off sharply after the trial setbacks, dragging the SMI lower and reviving the long-running debate over whether the benchmark is still a usable diversification tool. The issue is not academic. Index concentration can magnify idiosyncratic corporate risk, distort portfolio construction and force institutional investors to rethink whether they can even own the benchmark in size. Some institutions are barred from allocating to indices that are this concentrated.

That is exactly why the Swiss Leader Index exists. The SLI caps the four largest names at 9% each, roughly half the maximum weight allowed in the SMI, making it a more balanced vehicle for investors who want Switzerland without putting nearly half their capital behind three giant names. Yet even that trade-off is evolving. The SLI outperformed the SMI between 2019 and 2025, but this year the pattern has flipped, with the SMI ahead despite Novartis’ correction, helped by stronger global pharma shares, Nestlé’s rebound from cheap valuations and UBS’s performance. In other words, concentration cuts both ways: it can hurt on the way down, but when the heavyweights rally, the benchmark can outperform everything else around it.

For investors, the bigger lesson is that index ownership is not the same as diversification. The SMI is effectively a concentrated defensive bet, while the S&P 500 has become a concentrated technology bet; the common thread is that both are far less balanced than their labels suggest. That is why passive flows can still create active risk. When the few biggest names move, they dictate the return profile of the whole index and, by extension, many pension funds and ETF portfolios that track it.

The opportunity here is not in betting blindly on the index, but in positioning around the distortion it creates. If you want Swiss exposure, the more rational play may be the SLI or selective ownership of the underlying winners and losers rather than the headline benchmark. The market underestimates how much this concentration can amplify moves in Roche, Novartis and Nestlé — and how quickly a single clinical disappointment or valuation reset can become a national-market event.

The takeaway: Swiss equities remain investable, but the SMI is no longer a clean proxy for the country. Investors who want the best risk-adjusted exposure should treat concentration itself as the trade — and favor structures that reduce the three-stock dependency before the next shock makes it painfully obvious.